The generic name for Xofluza is baloxavir marboxil [1].
When does Xofluza's patent expire?
Patent exclusivity for Xofluza (baloxavir marboxil) is set to expire in 2032 [2]. However, this timeline can be affected by various factors, including potential patent challenges and the approval of generic versions [3].
How does baloxavir marboxil work?
Baloxavir marboxil is an antiviral medication that inhibits the cap-dependent endonuclease activity of the influenza virus polymerase acidic endonuclease [1]. This mechanism stops the virus from replicating.
What are the alternatives to Xofluza?
Other influenza antiviral medications include oseltamivir (Tamiflu), zanamivir (Relenza), and peramivir (Rapivab) [4]. These drugs work through different mechanisms, primarily by inhibiting the neuraminidase enzyme of the influenza virus, which is essential for the release of new virus particles from infected cells [4].
What is the clinical data on baloxavir marboxil?
Clinical studies have shown that baloxavir marboxil effectively reduces the duration of influenza symptoms. For example, one study demonstrated that baloxavir marboxil shortened the time to alleviation of symptoms by approximately 24 hours compared to a placebo in otherwise healthy individuals [5]. It is also approved for the treatment of influenza in patients aged 12 years and older with acute uncomplicated influenza who have been symptomatic for no more than 48 hours and do not have risk factors for developing complications [6].
What are the potential risks or side effects of baloxavir marboxil?
Potential side effects of baloxavir marboxil include diarrhea, nausea, and bronchitis [1]. It is important to consult a healthcare professional for a complete list of potential risks and to discuss individual concerns.
Who manufactures Xofluza?
Xofluza is manufactured by Shionogi Inc. [7].
Can generic versions of Xofluza be available before patent expiry?
While patent expiry in 2032 generally indicates when generic competition can begin, it is possible for authorized generic versions to become available sooner. However, direct generic entry typically occurs after the expiration of primary patents [3].
Sources:
[1] https://www.drugs.com/mtm/xofluza.html
[2] https://drugpatentwatch.com/
[3] https://drugpatentwatch.com/
[4] https://www.cdc.gov/flu/treatment/what-to-do-if-you-get-sick.html
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa1715711
[6] https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210703s000lbl.pdf
[7] https://www.shionogi.com/